APYX

Image source: The Motley Fool. Thursday, Aug. 6, 2026 at 4:30 p.m. ET President and Chief Executive Officer - Charles Goodwin Chief Financial Officer - Matthew Hill Operator: Good afternoon, ladies and gentlemen, and welcome to the Apyx Medical 2Q '26 Earnings Conference Call. [Operator Instructions ] This call is being recorded on Thursday, August 6, 2026. I would now like to turn the conference over to Jeremy Feffer, LifeSci Advisors. Please go ahead. Jeremy Feffer: Thank you, and welcome, everyone, to our second quarter 2026 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer; and Matt Hill, Chief Financial Officer of Apyx. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements. That are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated. Including, without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website. I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please go ahead. Charles Goodwin: Thank you, Jeremy, and thank you all for joining us today. For our usual format on these quarterly calls, I will begin with a review of our performance over the past several months and then turn the call over to Matt for a review of our second quarter 2026 financial results, along with our guidance for full year 2026. We will then open the call for questions. Let me begin with a review of a few key highlights from our second quarter 2026 performance. We reported quarterly revenue of $13.9 million compared to $11.4 million in the same period last year, an increase of 22%. This growth was driven by a 28% increase in sales of our Surgical Aesthetics products to $12.4 million for the second quarter, primarily attributable to sales of our AYON Body Contouring System, increased Renuvion generator sales internationally and increased volume of single-use handpieces domestically. This marks our fourth consecutive quarter of AYON sales following its full commercial launch in September of 2025, and we are pleased to see increasing awareness of and demand for the platform across U.S. market. U.S. surgeons are increasingly recognizing the value of our integrated all-in-one body contouring platform, which combines the core technologies they rely on every single day into a single streamlined system. We believe the growing adoption reinforces AYON's differentiated value proposition. We recently took another important step in expanding AYON's capabilities during the quarter when we received expanded 510(k) clearance from the FDA to add power liposuction to the platform. Power liposuction uses a reciprocating cannula to support more efficient fat removal while reducing the physical effort required of the surgeon. Since receiving clearance, we conducted a limited commercial launch of the reusable power liposuction handpiece with key surgeons in targeted geographies. Based on positive feedback, we commenced initial commercial shipments in June of 2026. Overall, the sales and interest that we are seeing in AYON comes at an important time for the body contouring market. As we have discussed on prior calls, the continued rapid adoption of GLP-1 medications is reshaping the patient population and creating what we believe will be a meaningful long-term opportunity for our business. While these therapies are helping a growing number of patients achieve significant weight loss, many are left with loose or lax skin that cannot be adequately addressed through nonsurgical treatments. Once these patients reach or approach their target weight, we believe many will seek procedures to address skin laxity, excess fat and overall body contouring in a more comprehensive manner. AYON seamlessly combines advanced fat removal technologies, Renuvion's tissue contraction and electrosurgical capabilities and empower surgeons to deliver the most comprehensive body contouring treatments for patients while positioning Apyx to address this growing market. We believe in science-based medicine and our clinical strategy is an important part of establishing that value proposition. During the quarter, a retrospective study of 113 patients showed that a combination procedure using Renuvion and liposuction was associated with statistically significantly higher patient satisfaction, lower rates of abdominoplasty and surgical revision and a comparable complication rate versus procedures that use liposuction alone. These findings are important because they suggest that Renuvion may help surgeons deliver a more satisfying aesthetic outcome while potentially reducing the need for more invasive or follow-on procedures without increasing the observed complication rate. We also reported data from prospective study evaluating a single session treatment combining Avéli and Renuvion. The study demonstrated visible improvements in cellulite and skin laxity, including measurable reductions in dimple volume, surface area and depth. In a subset of patients, histological analysis also showed increases in collagen and elastin through 180 days, providing evidence of progressive tissue remodeling following treatment. Together, these peer-reviewed publications add to the clinical foundation supporting Renuvion and demonstrate its potential value across a broader range of aesthetic body contouring procedures. In addition, the publications reinforce the important point that as patients' needs become more complex, surgeons increasingly require technologies that can address not only fat removal, but also skin quality, laxity and structural factors that influence the final aesthetic result. We also took the opportunity this quarter to build broader awareness of our platform, showcasing Renuvion and AYON at Miami Swim Week through our Body by Apex showcase. The event featured real Renuvion patients sharing their treatment journeys and walking the runway, allowing us to highlight the aesthetic outcomes and the self-confidence those patients gain from their procedures. This year's event underscored the progress we have made since last summer. At that time, AYON was still in the early stages of its commercial journey. This year, we returned with a commercially available platform supported by growing physician engagement, real-world experience and enhanced capabilities through the FDA clearance of power liposuction, which has resulted in AYON gaining traction across the market. Together, those milestones reflect the disciplined execution of our commercial strategy and reinforce the foundation of the opportunity ahead. These accomplishments demonstrate the progress we are making in executing our commercial strategy and reinforce our confidence in the long-term opportunity for our cohesive platform of AYON and Renuvion. Before I wrap up, I would like to briefly touch on our recent announcement that Stavros Vizirgianakis has been appointed Executive Chairman of our Board of Directors. Over the past 2 years, Stavros has become an increasingly important partner to both our Board and management team. He has been deeply engaged in helping shape our strategic priorities, supporting key financing initiatives and strengthening our operational focus and providing valuable guidance as we execute our commercial strategy. Formalizing his role as Executive Chairman recognizes the level of involvement he already has within the company and reflects our shared commitment to creating long-term shareholder value. Stavros brings decades of leadership experience and extensive industry network and a proven track record of building and growing health care businesses. I look forward to continuing to work closely with him as we execute on the significant opportunities ahead for Apyx. I will now turn the call over to Matt for a review of our second quarter 2026 financial results in more detail, along with our financial guidance for 2026. Matthew Hill: Thank you, Charlie. Before I get started, please note that all references to our second quarter financial results will be on a GAAP and year-over-year basis, unless noted otherwise. As Charlie mentioned, total revenue for the second quarter of '26 increased 22% to $13.9 million compared to $11.4 million in the prior year period. Revenue for the Surgical Aesthetics segment increased 28% or $2.7 million to $12.4 million compared to $9.7 million for the prior year period. This growth was driven by sales of AYON, increased sales of generators internationally and increased volume of single-use handpieces domestically. Turning to the OEM segment. Sales decreased 12% or approximately $0.2 million to $1.5 million for the second quarter of '26 compared to $1.7 million for the second quarter of '25. The decrease in OEM sales was due to a decrease in sales volume to existing customers. With the increased focus on surgical aesthetics, we continue to expect our OEM segment revenue will decrease for the year, and this trend will continue over time. Domestic revenue increased 21% year-over-year to $9.4 million and international revenue increased 24% year-over-year to $4.5 million for the second quarter of '26. Gross profit for the second quarter '26 increased 25% to $8.9 million compared with $7.1 million in the prior year period. Gross profit margin for the second quarter of '26 increased to 63.9% compared to 62.3% in the prior year period. The increase in gross margin was primarily attributable to mix between our segments with Surgical Aesthetics comprising a higher percentage of total sales and product mix within our OEM segment. This was partially offset by tariffs that began affecting us in the second half of 2025. Operating expenses increased to $10.7 million for the second quarter of '26 compared to $9.7 million for the prior year period. The increase was driven by $1.0 million increase in selling, general and administrative expenses and $0.3 million increase in salaries and related costs, partially offset by a $0.3 million decrease in professional services. Loss from operations was $1.8 million compared with a loss from operations of $2.6 million for the second quarter of '25. Net loss attributable to stockholders was $3.2 million or $0.07 per share for the second quarter of '26 compared with $3.8 million or $0.09 per share in the prior year period. Adjusted EBITDA loss was $0.7 million for the second quarter of '26 compared to an adjusted EBITDA loss of $2.0 million in the second quarter of '25. As a reminder, we provide a detailed reconciliation from the net loss attributable to stockholders to non-GAAP adjusted EBITDA in our earnings press release. For the 3 months ended June 30, 2026, net cash used in operating activities was $3.5 million compared to $1.2 million used in the prior year period. The increase was primarily due to changes in working capital, partially offset by a reduction in operating loss. As of June 30, 2026, the company had cash and cash equivalents of $27.6 million. We believe, based on our projections, including uptake of the AYON platform, working capital management and our strict cost controls, we expect to maintain sufficient liquidity into 2028. We are focused on growing sales, managing expenses and getting to cash flow positive as quickly as possible. Turning to our 2026 guidance. We are reaffirming our full year total revenue guidance in the range of $59.0 million to $60.0 million compared with $52.8 million reported for the year ended December 31, 2025. Our guidance continues to assume Surgical Aesthetics segment revenue in the range of $54.0 million to $55.0 million compared with approximately $45.3 million for 2025, and OEM revenue of approximately $5.0 million compared with approximately $7.5 million for 2025. In addition, we continue to expect gross margins in the range of 62% to 63% and total operating expenses not to exceed $45.0 million for the full year. This completes our prepared remarks. Charlie and I will now open the call for questions. Operator? Operator: [Operator Instructions] We will now take our first question, and this comes from Dave Turkaly from Citizens. David Turkaly: Charlie, I got -- I think I have a bunch of questions. I want to ask that you may not want to answer, but let me just start off by asking you in terms of the users that you're hitting with the new AYON product, are there non-Renuvion folks? And any people sort of like outside of your core plastic docs? Charles Goodwin: Yes. So the answer to the first part of the question is yes. We are getting people that have never used Renuvion before that are buying the AYON platform. So that is the first part of your question. And the second part of your question is, for the most part, it's all plastic or cosmetics that are doing, obviously, bodies and seeing these GLP-1 patients coming into their practice. Those are the people who are acquiring AYON right now. David Turkaly: Great. I think we all understand like the footprint difference of having kind of an all-in-one option, but it seems like there's some other benefits. You mentioned Power Lipo, but even with your ultra Lipo and some of the other features that could save the physician's time. So I was wondering if you could just maybe walk us through that quickly. Charles Goodwin: Yes. It's a good question because what you see from the outside is just the fact that everything is put together in a nice streamlined package, but that really is the least important part of the story. The most important part of the story is that every technology that is in AYON is better than the existing technologies that exist today. And remember, the liposuction that we have for the ultrasonic liposuction, that has been out since we originally launched AYON, but we just got approval for the power-assisted piece in May of this last year. And the power-assisted piece is a very important part of AYON because that is the part that defines and sculpts the body and actually removes the fat or puts the fat back into other areas, and that is the part that takes the longest in the procedure. So the ultrasonic separates the fat and then the Power Assist comes in and takes the fat out. And then through our closed-loop contouring, you can put it back in. But let's not forget that in the quarter, we just did a soft launch in the quarter, and we got feedback from the physicians. That feedback was incredibly well received on the Power Lipo product. In fact, it was exceptional. And then we only started to ship to a very few units in June, okay? So we still have work to do as far as building Power Lipo handpieces and getting them out to customers that are still waiting for them. Operator: And the next question comes from Alex Fuhrman from Lucid Capital Markets. Alex Fuhrman: Congratulations on another strong quarter of double-digit growth. I wanted to ask about gross margin. It was up very nicely year-over-year in the first and second quarter this year. It looks like the guidance implies that it's going to come in a little bit sequentially. Can you talk a little bit about what's driving that? It seems like the mix shift to surgical aesthetics has certainly been helping things, and that's expected to continue. So any color on what's driving that change in gross margin would be helpful. Charles Goodwin: Yes. Look, I don't know that it is too much of a change. There's always a mix in there between international and OUS and U.S. And so I don't know that fundamentally that there's any change. It has overperformed the first 2 quarters, which is obviously very nice. We're very happy with that. But remember, we're in the process of rolling out the Power Lipo right now. And obviously, the first ones of anything that you make are going to be the most expensive ones, and you're going to see that get better and better as time goes on as manufacturing has more throughput as we get better at making them and all of those things. And so when we're looking at the second half, remember, we're just gearing up on the Power Lipo handpiece. And so there's -- we're looking at that and making sure that we're able to deliver and do the things that we need to do there. Operator: The next question comes from Matthew Hewitt from Craig-Hallum. Tollef Kohrman: This is Tollef Kohrman on for Matt Hewitt. So for Power Lipo, is that at all embedded into the guidance? Charles Goodwin: When you say embedded into the guidance, yes. I mean, Power Lipo is always something that we had anticipated to have in the back half of the year. And yes, it is in the guidance. Tollef Kohrman: Okay. And then are you guys expecting any tariff refunds this year? Charles Goodwin: We are in the process of going through that. We would expect to receive some, and we don't really have any idea exactly what that would be at this time. And if we did get any tariff refunds, they are not in the current guidance that is out there now. Operator: And the next question comes from Yi Chen from H.C. Wainwright. Yi Chen: Could you remind us how many AYON systems have been placed since launch? And if a customer purchased the system today, do they -- do you expect all of them to purchase it with the power liposuction attachment? Charles Goodwin: Yes. So we have not given the number of AYON that are in the market. So I will not be able to give you that number today. But we would expect that the vast majority of people who are buying an AYON would have a power Lipo would have Power Lipo with it. I would say north of 95% of people would have Power Lipo with it. Yi Chen: So adding the power liposuction does increase recurring handpiece revenue, right? Or it just primarily improved the platform's competitiveness? Charles Goodwin: Well, so both. But remember, the Power Lipo handpiece is and probes are reusable with a useful life. So -- and they're measured in hours. So the handpieces would need to be replaced over time. Typically, a busy practice would go through 2, 3, 4 handpieces a year and then the probes, obviously, with them, too. So they are reusable, but they have a useful life. Yi Chen: Okay. And I don't know if you have some preliminary data you can share with us that for surgeons that purchased the AYON system, what is the average first year or second year recurring consumable revenue? Charles Goodwin: Yes. So the -- we have talked about the procedure reoccurring revenue. There is obviously the Renuvion handpiece. And then there is about an extra $100 of tubings and canisters per case that would be recurring on the AYON system. Operator: [Operator Instructions] No further questions that came through at this time. I will now turn the call over back to Charlie Goodwin. Please go ahead, sir. Charles Goodwin: Yes. I'd like to thank everybody for attending the call today. We're very pleased with the momentum in the business this quarter, and we look forward to the full commercial launch of power liposuction in the third quarter as the next step in building our AYON platform. We appreciate all the support we have received from our shareholders during this time, and I can't thank you all enough. Have a good night. Operator: Thank you. This concludes our conference call for today. Thank you all for participating. You may now disconnect. Before you buy stock in Apyx Medical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apyx Medical wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $400,209!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,375,393!* That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 13, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Apyx Medical (APYX) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Apyx Medical Corp (NASDAQ:APYX) reported a 22% increase in quarterly revenue to $13.9 million, driven by a 28% surge in surgical aesthetics product sales. The company received expanded FDA 510(k) clearance for power liposuction on its Aion platform, enhancing its body contouring capabilities and driving new commercial shipments. Apyx Medical Corp (NASDAQ:APYX) is capitalizing on the growing GLP-1 weight-loss trend, positioning its Aion platform to address the resulting demand for skin laxity and body contouring procedures. Clinical data presented during the quarter showed that combining Renuvion with liposuction led to higher patient satisfaction and lower revision rates, strengthening the product's value proposition. Gross profit margin improved to 63.9% from 62.3% in the prior year, driven by a favorable product mix shift toward the higher-margin surgical aesthetics segment. The company reaffirmed its full-year 2026 revenue guidance of $59 million to $60 million, reflecting confidence in continued growth and market adoption. Apyx Medical Corp (NASDAQ:APYX) reported a net loss of $3.2 million for the second quarter, though this was an improvement from the $3.8 million loss in the prior year period. OEM segment sales decreased 12% year-over-year due to lower sales volume to existing customers, a trend the company expects to continue as it focuses on surgical aesthetics. The company's cash used in operating activities increased to $3.5 million in the second quarter, up from $1.2 million in the prior year period, due to changes in working capital. Gross margins are expected to face pressure in the second half of 2026 as the company ramps up production of the new power liposuction handpieces, which are initially more expensive to manufacture. Tariffs that began affecting the company in the second half of 2025 continue to partially offset gross margin improvements, creating ongoing cost headwinds. The company did not provide specific numbers on Aion system installations, leaving investors without a clear metric to gauge the pace of market penetration. Warning! GuruFocus has detected 2 Warning Signs with APYX. Is APYX fairly valued? Test your thesis with our free DCF calculator. Q: Are the new users of the Aeon product non-Renuvion users, and are they outside of your core plastic surgeon demographic? A: Charlie Goodwin (CEO): Yes, we are getting people who have never used Renuvion before buying the Aeon platform. For the most part, the buyers are plastic or cosmetic surgeons who are seeing GLP-1 patients in their practices and are acquiring Aeon for body contouring procedures. Q: Beyond the streamlined all-in-one footprint, what are the other benefits of the Aeon system, such as power liposuction, that save physicians time? A: Charlie Goodwin (CEO): The most important part is that every technology in Aeon is better than existing technologies. The power-assisted liposuction piece is crucial because it defines, sculpts, and removes fat, which is the longest part of the procedure. The ultrasonic component separates the fat, and the power piece removes it. We did a soft launch of the Power Lipo product in the quarter, and the feedback from physicians was exceptional. We only started shipping a few units in June and still have work to do to build handpieces for customers waiting for them. Q: Gross margin was up nicely year-over-year in the first and second quarters, but guidance implies it will come in a little sequentially. What is driving that change? A: Charlie Goodwin (CEO): There isn't a fundamental change; there is always a mix between international and US sales. The margin has overperformed in the first two quarters, which we are happy about. However, we are in the process of rolling out the Power Lipo, and the first units of any new product are the most expensive to make. As manufacturing throughput improves, costs will come down. In the second half, we are gearing up on the Power Lipo handpiece, which impacts the margin outlook. Q: Was the Power Lipo launch embedded into the full-year guidance? A: Charlie Goodwin (CEO): Yes, Power Lipo was always anticipated to be in the back half of the year, and it is included in the guidance. Q: Are you expecting any tariff refunds this year? A: Charlie Goodwin (CEO): We are in the process of going through that and would expect to receive some, but we don't have any idea exactly what that would be at this time. If we did get any tariff refunds, they are not included in the current guidance. Q: How many Aeon systems have been placed since launch, and do you expect all customers to purchase it with the power liposuction attachment? A: Charlie Goodwin (CEO): We have not given a number of Aeons in the market, so I cannot provide that today. However, we would expect that the vast majority of people buying an Aeon would have Power Lipo with itI would say north of 95% of people would have it. Q: Does adding power liposuction increase recurring handpiece revenue, or does it primarily improve the platform's competitive position? A: Charlie Goodwin (CEO): The Power Lipo handpieces and probes are reusable with a useful life measured in hours. A busy practice would typically go through two, three, or four handpieces a year, along with the probes. So, they are reusable but have a useful life, which does contribute to recurring revenue. Q: Do you have preliminary data on the average first-year or second-year recurring consumable revenue for surgeons who purchased the Aeon system? A: Charlie Goodwin (CEO): We have talked about the recurring revenue, which includes the Renuvion handpiece and an extra $100 of tubing and canisters on the system. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Interested in Apyx Medical Corporation? Here are five stocks we like better. Revenue rose 22% to $13.9 million in the second quarter, driven by a 28% increase in surgical aesthetics sales to $12.4 million, while OEM revenue declined 12% to $1.5 million. Apyx expanded FDA clearance for the AYON Body Contouring System to include power liposuction, began initial shipments in June, and plans a full commercial launch in the third quarter. Management expects more than 95% of AYON buyers to adopt the power-liposuction capability, creating recurring handpiece and procedure-related revenue. The company narrowed its net loss and adjusted EBITDA loss, ended the quarter with $27.6 million in cash, and reaffirmed 2026 revenue guidance of $59 million to $60 million, with gross margin expected at 62% to 63%. Apyx Medical (NASDAQ:APYX) reported second-quarter revenue growth of 22% as sales in its surgical aesthetics business increased, led by adoption of its AYON Body Contouring System, international generator sales and domestic demand for single-use handpieces. Total revenue for the quarter ended June 30 rose to $13.9 million from $11.4 million a year earlier. Surgical aesthetics revenue increased 28% to $12.4 million, while original equipment manufacturer, or OEM, revenue fell 12% to $1.5 million as sales volume to existing customers declined. → 3 Drone Stocks That Should Soar After the Summer Slump “This marks our fourth consecutive quarter of AYON sales following its full commercial launch in September 2025,” President and Chief Executive Officer Charlie Goodwin said. He said the company has seen increasing awareness and demand for the platform in the U.S. market. During the quarter, Apyx received expanded FDA 510(k) clearance to add power liposuction to AYON. The technology uses a reciprocating cannula intended to support fat removal while reducing the physical effort required by surgeons. → Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth The company conducted a limited commercial launch of a reusable power-liposuction handpiece with selected surgeons in targeted markets after receiving clearance. Goodwin said feedback from physicians was “exceptional,” and Apyx began initial commercial shipments in June. He said the company plans a full commercial launch in the third quarter. In response to analyst questions, Goodwin said AYON purchasers include physicians who had not previously used Renuvion. He said customers are primarily plastic or cosmetic surgeons treating body-contouring patients, including patients who have experienced weight loss associated with GLP-1 medications. → Jersey Mike's Serves Fresh Gains After IPO Stumble Goodwin said the company expects more than 95% of customers purchasing an AYON system to include the power-liposuction capability. While the handpieces and probes are reusable, they have a useful life measured in hours and require replacement over time, he said. A busy practice may use two to four handpieces annually, according to Goodwin. The company did not disclose the number of AYON systems placed since launch. Goodwin also noted that each AYON procedure can generate recurring revenue from Renuvion handpieces as well as approximately $100 in tubing and canisters per case. Management discussed two clinical studies during the call. A retrospective study involving 113 patients found that a combination of Renuvion and liposuction was associated with statistically significantly higher patient satisfaction, lower rates of abdominoplasty and surgical revision, and comparable complication rates versus liposuction-only procedures, Goodwin said. A separate prospective study evaluating a single-session treatment combining Avéli and Renuvion showed visible improvements in cellulite and skin laxity, including reductions in dimple volume, surface area and depth. In a subset of patients, histological analysis showed increases in collagen and elastin through 180 days, according to the company. Goodwin said Apyx views the growing use of GLP-1 medications as a long-term market opportunity, as patients who experience substantial weight loss may seek surgical treatments for loose skin, skin laxity, excess fat and other body-contouring needs. The company also showcased Renuvion and AYON at Miami Swim Week through its “Body by Apyx” event, which featured Renuvion patients discussing their treatment experiences and walking a runway. Gross profit increased 25% to $8.9 million, while gross margin expanded to 63.9% from 62.3% in the prior-year quarter. Chief Financial Officer Matt Hill said the margin improvement primarily reflected a greater contribution from surgical aesthetics revenue and product mix within OEM. Tariffs that began affecting the company in the second half of 2025 partially offset those factors. Operating expenses rose to $10.7 million from $9.7 million. The increase included a $1 million rise in selling, general and administrative expenses and a $0.3 million increase in salaries and related costs, partly offset by a $0.3 million decrease in professional services. Loss from operations narrowed to $1.8 million from $2.6 million. Net loss attributable to stockholders was $3.2 million, or $0.07 per share, compared with $3.8 million, or $0.09 per share, a year earlier. Adjusted EBITDA loss improved to $0.7 million from $2 million. Net cash used in operating activities was $3.5 million during the quarter, compared with $1.2 million in the prior-year period, primarily due to working-capital changes. As of June 30, the company had $27.6 million in cash and cash equivalents. Hill said Apyx expects to maintain sufficient liquidity into 2028 based on projected AYON uptake, working-capital management and cost controls. Apyx reaffirmed its full-year 2026 revenue guidance of $59 million to $60 million, compared with $52.8 million in 2025. The outlook assumes surgical aesthetics revenue of $54 million to $55 million and OEM revenue of approximately $5 million. Expected 2026 gross margin: 62% to 63% Expected total operating expenses: no more than $45 million Expected 2026 OEM revenue: approximately $5 million, down from approximately $7.5 million in 2025 Goodwin said power-liposuction revenue is included in the company’s guidance for the second half of the year. He added that Apyx is pursuing possible tariff refunds, though any such refunds are not included in current guidance. The company also announced that Stavros Vizirgianakis has been appointed executive chairman of its board. Goodwin said Vizirgianakis has supported the company’s strategic priorities, financing initiatives and operational focus over the past two years. Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company's product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology. Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Apyx Medical Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026 Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million Management to host a conference call today at 4:30 p.m. ET CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its second quarter ended June 30, 2026. Recent Financial and Operating Highlights: Reported total revenue of $13.9 million in the second quarter of 2026, compared with $11.4 million in the same period last year. Net loss attributable to stockholders of $3.2 million in the second quarter of 2026, compared with a net loss attributable to stockholders of $3.8 million in the second quarter of 2025. Adjusted EBITDA loss was $0.7 million for the second quarter of 2026, compared with an Adjusted EBITDA loss of $2.0 million for the second quarter of 2025. Received expanded FDA 510(k) clearance for the AYON Body Contouring System to include power liposuction and commenced a limited commercial launch of the reusable power liposuction handpiece with targeted early adopters. Published retrospective clinical data demonstrating that Renuvion used in combination with liposuction was associated with significantly higher patient satisfaction, lower abdominoplasty and revision rates and comparable complication rates versus liposuction alone. Reported positive clinical data demonstrating significant improvements in cellulite appearance and skin laxity following a single-session combination treatment utilizing Avéli and Renuvion. Showcased Renuvion and the AYON Body Contouring System at Miami Swim Week through the Body by Apyx event, highlighting real patient transformations and increasing awareness among consumers and aesthetic providers. “We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strategy. As a result, we reported 28% growth for the Surgical Aesthetics segment and expect AYON to continue to drive growth through the second half of the year,” said Charlie Goodwin, President and Chief Executive Officer. “U.S. Surgeons continue to recognize the value of an all-in-one body contouring platform that brings together the technologies they rely on every day. With the recent FDA clearance of AYON's power liposuction capability, we are executing a measured rollout with key surgeons ahead of a initial commercial shipments in June. Alongside the expanding body of clinical evidence supporting Renuvion, these milestones reinforce our confidence in the long-term growth opportunity for our business.” The following tables present revenue by reportable segment and geography: Second Quarter 2026 Results: Total revenue for the three months ended June 30, 2026 increased 22% to $13.9 million compared with $11.4 million in the prior year period. Surgical Aesthetics segment sales increased 28%, or $2.7 million, to approximately $12.4 million for the three months ended June 30, 2026, when compared with $9.7 million for the three months ended June 30, 2025. The Surgical Aesthetics sales increase was driven by sales of AYON, which commenced with the commercial launch in the third quarter of 2025, increased sales of generators internationally and increased volume of single-use handpieces domestically. These increases were partially offset by decreases in domestic sales of standalone generators. OEM segment sales decreased 12%, or $0.2 million, to approximately $1.5 million for the three months ended June 30, 2026, when compared with $1.7 million for the three months ended June 30, 2025. The decrease in OEM sales was due to a decrease in sales volume to existing customers. With the increased focus on Surgical Aesthetics, the Company expects that OEM segment revenue will decrease for the year and that this trend will continue over time. Gross profit for the three months ended June 30, 2026, increased 25% to $8.9 million, compared with $7.1 million for the same period in the prior year. Gross margin for the three months ended June 30, 2026, was 63.9%, compared to 62.3% for the same period in 2025. The increase in gross margin for the three months ended June 30, 2026 from the prior year period is primarily attributable to mix between reportable segments with Surgical Aesthetics comprising a higher percentage of total sales and product mix within the OEM segment. This was partially offset by tariffs that began affecting the Company in the second half of 2025. Operating expenses increased to $10.7 million for the three-month periods ended June 30, 2026, compared with $9.7 million for the same period last year. The increase in operating expenses was driven by a $1.0 million increase in selling, general and administrative expenses and a $0.3 million increase in salaries and related costs, partially offset by a $0.3 million decrease in professional services. Other expense, net was relatively flat at $1.1 million for each of the three months ended June 30, 2026 and 2025. Net loss attributable to stockholders was $3.2 million, or $0.07 per share, for the three months ended June 30, 2026, compared with $3.8 million, or $0.09 per share, in the prior year period. Adjusted EBITDA loss for the three months ended June 30, 2026 was $0.7 million as compared with an Adjusted EBITDA loss of $2.0 million for the three months ended June 30, 2025. For the three months ended June 30, 2026, net cash used in operating activities was $3.5 million, compared with $1.2 million used in the three months ended June 30, 2025. The increase was primarily due to changes in working capital, partially offset by a reduction in operating loss. As of June 30, 2026, the Company had cash and cash equivalents of $27.6 million. Management believes based on its projections, including the uptake of the AYON platform, working capital management and its strict cost controls, the Company will yield cash through 2027. Financial Guidance for Full Year 2026: The Company reaffirmed its financial guidance targets for the year ending December 31, 2026: Total revenue in the range of $59.0 million to $60.0 million, compared with $52.8 million reported for the year ended December 31, 2025. The Company continues to expect operating expenses of less than $45.0 million for the year ended December 31, 2026. Conference Call Details: Management will host a conference call at 4:30 p.m. Eastern Time today, August 6th, to discuss the results of the second quarter ended June 30, 2026, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 53282. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference. An archive of the webcast will be accessible approximately one hour after the live event ends on the Investor Relations section of the Company’s website (click here). Investor Relations Contact: Jeremy Feffer, Managing Director, LifeSci AdvisorsOP: [email protected] About AYON Body Contouring System™: AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery. About Apyx Medical Corporation: Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products including its Helium Plasma Platform Technology products marketed and sold as Renuvion®, the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is anFDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com. Cautionary Statement on Forward-Looking Statements: Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance. Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. Use of Non-GAAP Financial Measure: The Company has presented the following non-GAAP financial measure in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net loss attributable to stockholders (GAAP) plus income tax expense (benefit), interest income and expense, depreciation and amortization, stock-based compensation expense and other significant non-recurring items. We present the following non-GAAP measure of adjusted EBITDA because we believe such measure is a useful indicator of our operating performance. Our management uses adjusted EBITDA principally as a measure of our operating performance and believes that this measure is useful to investors because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that this measure is useful to our management and investors as a measure of comparative operating performance from period to period. The non-GAAP financial measure presented in this release should not be considered as a substitute for, or preferable to, the measures of financial performance prepared in accordance with GAAP.

As you might know, Apyx Medical Corporation (NASDAQ:APYX) just kicked off its latest first-quarter results with some very strong numbers. Apyx Medical outperformed estimates, with revenues of US$12m beating estimates by 19%. Statutory losses were US$0.05, 55% smaller thanthe analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Taking into account the latest results, the current consensus from Apyx Medical's four analysts is for revenues of US$59.6m in 2026. This would reflect a satisfactory 6.5% increase on its revenue over the past 12 months. Losses are forecast to balloon 28% to US$0.28 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$57.8m and losses of US$0.36 per share in 2026. So it seems there's been a definite increase in optimism about Apyx Medical's future following the latest consensus numbers, with a considerable decrease in the loss per share forecasts in particular. Check out our latest analysis for Apyx Medical It will come as no surprise to learn thatthe analysts have increased their price target for Apyx Medical 8.3% to US$6.50on the back of these upgrades. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Apyx Medical, with the most bullish analyst valuing it at US$8.00 and the most bearish at US$6.00 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation. Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting Apyx Medical's growth to accelerate, with the forecast 8.8% annualised growth to the end of 2026 ranking favourably alongside historical growth of 4.2% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 7.9% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Apyx Medical is expected to grow at about the same rate as the wider industry. The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. There was also an upgrade to revenue estimates, although as we saw earlier, forecast growth is only expected to be about the same as the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Apyx Medical going out to 2028, and you can see them free on our platform here.. Plus, you should also learn about the 2 warning signs we've spotted with Apyx Medical . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Image source: The Motley Fool. Thursday, May 7, 2026 at 8 a.m. ET President and Chief Executive Officer — Charles D. Goodwin Chief Financial Officer — Matthew Hill Charles Goodwin: Thank you, Jeremy, and thank you all for joining us today. For our usual format on these quarterly calls, I will begin with a review of our performance over the past several months and then turn the call over to Matt for a review of our first quarter 2026 financial results, along with our updated guidance for full year 2026. We will then open the call for your questions. Let me begin with a review of a few key highlights from our first quarter 2026 performance. We reported total quarterly revenue of $12.5 million compared to $9.4 million in the same period last year. This growth was driven by a 36% increase in sales of our Surgical Aesthetics products to $10.7 million for the first quarter, which was primarily attributable to the continued strong sales ramp of our AYON body contouring system in the U.S., demand for single-use handpieces worldwide and increase in Renuvion generator sales internationally. This represents our second full quarter of AYON sales following its full commercial launch in September 2025. Notably, while demand from our existing generator and Renuvion customer base continues to be strong, we are also generating a steady increase in engagement from new accounts, reflecting growing market awareness of AYON and increasing confidence in the breadth of its capabilities. Importantly, we continue to believe adoption remains in the early stages. Over these past several months, I have been very pleased by how the commercial program for AYON has quickly ramped up activity. Our team has risen to the occasion and executed a disciplined, high-quality launch focused on training and workflow integration to achieve customer success. We are also pleased the release of AYON has coincided so well with the continued rapid adoption of GLP-1s. As of early 2026, roughly 1 in 8 U.S. adults report have taken a GLP-1 according to KFF health tracking polls and RAND reports. While approximately 6% of adults are currently using them, projections indicate that demand will continue to grow with estimates suggesting around 30 million Americans could be using GLP-1 treatments by 2030. The rapid weight loss that occurs using these drugs can lead to significant loose and lax skin that can only be effectively managed using a surgical intervention, and we believe Renuvion and AYON are the most advanced and effective method for treating loose and lax skin through body contouring. In addition to our revenue growth, we remain proud of the lean operating structure we implemented just over a year ago, which has materially reduced our operating expenses and cash burn. Those changes have strengthened our financial position and given us the flexibility to selectively reinvest in high-return growth initiatives, including the continued rollout of AYON and our broader surgical aesthetic strategy. Through the launch of AYON, we have expanded our customer relationships beyond individual technologies to a more comprehensive presence in the surgical suite, supporting a wider range of procedures and workflows. As I have mentioned previously, this is a groundbreaking body contouring offering designed by leading surgeons to address many of the challenges and limitations of existing systems. AYON is differentiated by its ability to integrate multiple core body contouring modalities on a single platform. allowing surgeons to streamline procedures, reduce equipment complexity and support optimal patient outcomes. As a result, we are seeing strong market receptivity, reinforcing our view that AYON is addressing a meaningful unmet need and adoption remains in the early stages. Building on this success and expanding upon the AYON suite of offerings even further, we anticipate FDA 510 clearance for the AYON platform to include power liposuction sometime this quarter. This is a core modality in modern body contouring procedures, and this clearance meaningfully expands AYON's functionality so that it now supports multiple advanced fat removal modalities on one platform. Importantly, we believe this further differentiates AYON in the market and broadens its addressable customer base. When cleared, our strategy for bringing the power liposuction functionality live, our team is implementing a limited commercial launch of power liposuction with highly targeted early adopters. Over the coming months, this program will serve as a critical proving ground to refine training, optimize utilization and evaluate the end-to-end customer experience. As we did with our AYON system in advance of its full launch, we will take a disciplined approach before scaling commercial implementation. We look forward to sharing further updates on this program as this program progresses. Looking beyond the U.S., we have tremendous opportunities following key regulatory approvals over just the past few quarters, including Renuvion in Asia. In South Korea, we experienced solid interest around the Apyx One Console and single-use handpieces immediately following our regulatory approval in December of 2025. As a reminder, South Korea represents an attractive market for Surgical Aesthetics and early customer interest and initial purchase activity reinforce our confidence in the long-term opportunity there. While it is still in the early stages, the initial customer demand for our generators and handpieces exceeded expectations, and we look forward to building on this initial momentum. To summarize, our long-term vision is simple: to walk into every surgical center and see an AYON at the center of the operating room, I believe we are off to an excellent start. I will now turn the call over to Matt for a review of our first quarter 2026 financial results in more detail, along with our updated financial guidance for 2026. Matthew Hill: Thank you, Charlie. Before I get started, please note that all references to our first quarter financial results will be on a GAAP and a year-over-year basis, unless noted otherwise. As Charlie mentioned, total revenue for the first quarter of '26 increased 32% to $12.5 million compared to $9.4 million in the prior year period. Revenue for Surgical Aesthetics segment increased 36% or $2.8 million to $10.7 million compared to $7.9 million for the prior year period. As Charlie referenced, this growth was driven by sales of AYON as we commenced our commercial launch towards the end of the third quarter of 2025, increased sales of generators internationally and increased volume of single-use handpieces in both domestic and international markets. These increases were partially offset by decreases in domestic sales of generators. Turning to the OEM segment. Sales increased 14% or approximately $0.2 million to $1.8 million for the first quarter of '26 compared to $1.5 million for the first quarter of '25. The increase in OEM sales was due to increases in sales volumes to existing customers, while OEM segment sales increased for the 3-month period with an increased focus on Surgical Aesthetics, we expect the OEM segment revenue will decrease for the year and that this trend will continue over time. Domestic revenue increased 20% year-over-year to $8.1 million and international revenue increased 63% year-over-year to $4.4 million for the first quarter of 2026. As a reminder, the medical device industry typically experiences some seasonality, with revenue trends generally lowest in the first and the third quarters and strongest in the second and fourth. Gross profit for the first quarter '26 increased 40% to $7.9 million compared with $5.7 million in the prior year period. Gross profit margin for the first quarter of '26 increased to 63.5% compared to 60.1% in the prior year period. The increase in gross margin for the 3 months ended March 31, 2026, from the prior year period is primarily attributable to mix between our segments, with the Surgical Aesthetics comprising a higher percentage of total sales and product mix within our OEM segment. This was partially offset by geographic mix with international sales comprising a higher percentage of total sales and tariffs that began affecting us in the second half of 2025. Operating expenses were relatively flat year-over-year with $8.8 million for the first quarter of '26 compared to $8.7 million for the prior year period. This was due to a combined $0.3 million increase in selling, general and administrative expenses and salaries and related costs, which was offset by a combined $0.2 million decrease in research and development and professional services expenses. Loss from operations was $0.9 million compared with a loss from operations of $3.1 million for the first quarter of 2025. Net loss attributable to stockholders was $2.1 million or $0.05 per share for the first quarter of '26 compared with $4.2 million or $0.10 per share in the prior year period. Adjusted EBITDA loss was $0.3 million for the first quarter of '26 compared to an adjusted EBITDA loss of $2.4 million in the first quarter of '25. As a reminder, we provide a detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted EBITDA loss in our earnings press release. For the 3 months ended March 31, 2026, cash used in operating activities decreased to $0.6 million compared to $0.7 million used in the prior year period. As of March 31, 2026, the company had cash and cash equivalents of $31.1 million. We believe based on our projections, including the uptake of the AYON platform, working capital management and our strict cost controls will yield cash through 2027. Turning to our '26 guidance. For the 12 months ended December 31, 2026, we announced an upward revision to our expected total revenue to be in the range of $59 million to $60 million, up from the previous guidance of $57.5 million to $58.5 million. This is compared with $52.8 million reported for the year ended December 31, 2025. Our revenue guidance assumes Surgical Aesthetics segment revenue in the range of $54 million to $55 million, up from the previous guidance of $53 million to $54 million. This is compared with approximately $45.3 million reported for the year ended December 31, 2025. OEM revenue is now expected to be approximately $5 million, up from the previous guidance of $4.5 million. This is compared with approximately $7.5 million for the year ended December 31, 2025. We now, depending on product and geographic mix, anticipate gross margins of approximately 62% to 63% for the year and total operating expenses not to exceed $45 million. This completes our prepared remarks. Charlie and I will now open the call for questions. Operator: [Operator Instructions] Your first question comes from David Turkaly from Citizens. David Turkaly: Congrats on the quarter and the guide. Charlie, just upfront really quick. I heard Matt say the U.S. generator sale decrease. And I noticed in the press release, you kind of pulled out a comment that said where AYON was not part of the sale. I just want to be clear because it seems like everything was really strong. Can you explain that detail that's there, like exactly what you're saying in the press release? Charles Goodwin: Yes. Yes, it's a good question, Dave. Basically, when we're selling AYON's now, we're counting those as AYON sales and not generator sales, even though if they're a brand-new customer, they would have a generator with them or if they're an RS3 upgrade, they would need to upgrade to the Apyx One. We don't capture those generators separately. We count it all as an AYON sale now. So more than anything else, it's just the geography. You're going to see that in the U.S. as we continue more people are going to buy full AYON systems as opposed to just buying generators as they were before. David Turkaly: And then as we look -- obviously, OUS was really strong. You called out South Korea. Will you bring AYON there? I think Apyx One is there right now, but is that the plan? And any color on sort of OUS rollout with that system? Charles Goodwin: Yes. If you look at the international business, it was a good, obviously, quarter for the international business. And as Matt and I both said, it was strength on handpieces, both from an international and a domestic perspective, but new generator sales and new upticks in South Korea, in particular, for outside the United States. And yes, we are working on registering AYON outside the United States, obviously. And so we will be working on various countries throughout this year. And as we make progress on that, we will obviously let the investors know of what we're doing there. But yes, we plan to have AYON registered everywhere in the world at some point in time. Operator: Next question comes from Sam Eiber from BTIG. Sam Eiber: Charlie, maybe a 2-part question on AYON. First, maybe I can get your thoughts on where you think we are in this rollout in the launch. It sounds like maybe you're starting to expand beyond the existing group of Renuvion accounts. And then just as a follow-up there on power-assisted liposuction, nice to hear that you're expecting label expansion this quarter. Has that been an impediment at all toward adoption? And with the label, could we expect some inflection thereafter? And how important is that going to be for surgeons? Charles Goodwin: Yes. No, it's a good question, and there's a lot in there. I'll try to unpack it for you. It's a multi-tiered question for sure. When we're talking about the existing Renuvion customers upgrading to AYON, we've actually just started with that. So that is a whole huge group of people that we have that could upgrade to AYON. And then obviously, to your point, it brings in a whole bunch of people that don't even have Renuvion at this time that could upgrade to that. And so we are -- if we're looking at AYON sales in the United States, and this is a baseball game, we're just in the top of the first inning. We're just basically getting started with this. As regards to power lipo, yes, to answer your question directly, there are people that are waiting for power lipo before they get AYON because some doctors do not use ultrasonic liposuction. They only use power liposuction. So if you look at the market, you've got groups of doctors that use both ultrasonic and power. You've got doctors that use ultrasonic by itself and not power. And then you've got doctors that use power liposuction and not ultrasonic. And obviously, the doctors that use only power liposuction are waiting for that label and that product to be available before they would get AYON. So from our perspective, power lipo is a huge indication for us and a huge approval because it rounds out the liposuction capabilities of AYON that give doctors both modalities on the system as it is today. So we do see it as being very significant. Sam Eiber: Okay. That's really helpful. Maybe I can just use my follow-up here on the demand environment. It sounds like consumables globally were up in the quarter. You guys have this tailwind with the GLP-1 wave that's coming in. But obviously, I know there's some geopolitical tensions, macroeconomic dynamics in the current environment. Just curious what you're seeing out in the field for underlying procedure demand at this moment. Charles Goodwin: Yes. I don't think there's any question that people that have been on these drugs and have lost the weight that they want to lose are looking for solutions to help their body. And yes, there is a lot of noise out there on the geopolitical front. There's no question about that. But from a demand perspective, we're still seeing patients coming into practices and wanting these procedures. Operator: Next question comes from Alex Fuhrman from Lucid Capital Markets. Alex Fuhrman: Congratulations on a really strong start to the year. It sounds like most of the AYON customers have been skewing towards new customers if you're only just starting to sell as an upgrade to your long-standing customers. Curious, Charlie, what kinds of clinics has it been resonating the most with? And are there practices that you had a hard time getting into when it was just Renuvion that are now taking another look with the full all-in-one? Charles Goodwin: Yes. So I actually want to just clarify one thing. So far, all the AYON's that we've sold, probably about 80% of them have been to Renuvion -- existing Renuvion customers. But if you look at the total base of Renuvion customers, we still have a long ways to go before we upgrade all of them, okay? And to answer your question about the new customers that weren't Renuvion customers before or Apyx customers before, to answer your question, yes, it is a huge help having AYON because now you're talking about the entire body contouring procedure. You're talking about adding technologies that increase efficiency for the doctor and their staff, lower patient -- lower procedure times for the patient, which is huge because they're less time under anesthesia. And we're even being told anecdotally from doctors that the outcomes are better for the patient. So yes, it is helping us immensely get into practices that we weren't in before for sure. Alex Fuhrman: Okay. That's really helpful. And then you referenced a study earlier in the call that suggested about 1 in 8 Americans have taken a GLP-1. Obviously, your business is doing very well here at a time when GLP-1 adoption is growing. Do you have any sense just kind of anecdotally, customers having a Renuvion treatment? I mean, do you feel like there's more than 1 in 8 or about that share that have taken a GLP-1? Just curious if that's been kind of a driver of the business or what you're hearing from your surgeons? Charles Goodwin: Yes. And we follow like Google searches and things like that, too, about what consumers are looking for and what they're seeing. And if you take a look at Google searches and you go over the last 12 months, one of the biggest increases is on loose skin. And so yes, we are seeing patients that are coming to the doctors' practices and they're asking for solutions for that. And it is -- if you look at, I think, the 3 biggest things in Google searches that are looking for right now, it's loose skin, body contouring and liposuction still. So people are looking for these solutions. They're taking these drugs. They're losing the weight. And obviously, they've got loose and lax skin after that. So we are seeing this in the marketplace. And I think that's -- that's why we're seeing the strength that we're seeing and the growth that we're having is because we think that the technologies and solutions that we're helping doctors with are squarely in the sights of what the patients are looking for. Operator: Next question would be from Matt Hewitt from Craig-Hallum. Tollef Kohrman: This is Tollef Kohrman on for Matt Hewitt. Congrats on a great quarter. So what's the assumed tariff impact embedded in the guide? And how should we think about any potential changes in the policy going forward? Charles Goodwin: Yes. Look, I don't know about changes in the guide. We're anticipating that the tariffs are going to remain throughout the rest of the year, and they're factored in there from, obviously, a cost and a gross profit point of view. So I mean, could things change and we have different tariffs? Absolutely. But one of the advantages that we have is that we manufacture both in Sofia, Bulgaria and Clearwater, Florida. And so we've been able to minimize the tariff impact so far to the business. But it is something that we're always looking at and finding the best way to keep our costs as low as they possibly can be. Tollef Kohrman: Excellent. And then earlier in the call, you cited you wanted to place AYON outside of the U.S., specifically everywhere. Just can you give a time line in key specific countries you're looking at right now? Charles Goodwin: So I can't give a time line, unfortunately, because I would -- anything I would give you would be wrong because it takes time in each individual country. But obviously, there's major places that we'd like to have AYON registered from a body contouring perspective. Obviously, all of Europe, we'd like to have it there. When we're looking at Latin America, we'd be looking at countries like Brazil and Colombia that do a lot of body contouring. We'd obviously be looking at the Middle East because there's a lot of business there and then key markets in Asia. So those would be the big areas that we'd be looking for AYON. Operator: [Operator Instructions] Ladies and gentlemen, this concludes our question-and-answer session. I would now hand the conference over to Charlie Goodwin for his closing comments. Charles Goodwin: Thank you, everybody, for attending the call. I want to really thank the entire Apyx Medical team for their tireless dedication and execution as we move into mid-2026 with tremendous energy and momentum towards driving growth. We appreciate all the support we have received from our customers and shareholders during this time. Thank you very much. Operator: Thank you. The conference of Apyx Medical has concluded. Thank you for your participation. You may now disconnect your line. Before you buy stock in Apyx Medical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apyx Medical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $475,926!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,296,608!* Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of May 8, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Apyx Medical (APYX) Q1 2026 Earnings Transcript was originally published by The Motley Fool

Interested in Apyx Medical Corporation? Here are five stocks we like better. Apyx reported Q1 revenue of $12.5 million (up from $9.4M), driven by the commercial ramp of the AYON body‑contouring system and a 36% increase in Surgical Aesthetics to $10.7 million, and management raised full‑year 2026 revenue guidance to $59–60 million (Surgical Aesthetics $54–55M). The company expects FDA 510(k) clearance for AYON power liposuction this quarter, which would add a core fat‑removal modality to the platform and is expected to broaden adoption among surgeons who have paused until power‑assisted capability is available. Profitability and liquidity improved: gross margin rose to 63.5%, net loss narrowed to $2.1 million (vs. $4.2M), adjusted EBITDA loss improved to $0.3 million, and cash totaled $31.1 million with management projecting cash runway through 2027. Apyx Medical (NASDAQ:APYX) reported first quarter 2026 revenue of $12.5 million, up from $9.4 million in the prior-year period, driven primarily by growth in its Surgical Aesthetics business and continued momentum from the company’s AYON body contouring system, which launched commercially in September 2025. Chief Executive Officer Charlie Goodwin said first quarter results reflected “continued strong sales ramp of our AYON body contouring system in the U.S., demand for single-use handpieces worldwide, and increase in Renuvion generator sales internationally.” Surgical Aesthetics revenue rose 36% year over year to $10.7 million. → Berkshire Hathaway’s Record Cash Hoard: Why and What's Next? Goodwin noted the quarter marked the company’s “second full quarter of AYON sales following its full commercial launch in September 2025.” He added that while demand from Apyx’s existing customer base remained strong, the company is also seeing “a steady increase in engagement from new accounts,” which he attributed to rising market awareness and growing confidence in AYON’s capabilities. Goodwin said the company continues to view adoption as early-stage. During the Q&A, Goodwin clarified that U.S. generator sales declined in part due to how the company is now classifying transactions. When Apyx sells AYON systems, it counts them as AYON sales rather than generator sales, even if the sale includes a generator component for a new customer or an upgrade to the Apyx One console. “We don’t capture those generators separately,” he said. “We count it all as an AYON sale now.” → A Prada Payday: Is AMC Back in Style? Goodwin also characterized the AYON rollout as still in its earliest innings. “If we’re looking at AYON sales in the U.S., and this is the baseball game, we’re just in the top of the first inning,” he said. Goodwin said the company anticipates FDA 510(k) clearance “sometime this quarter” for the AYON platform to include power liposuction, which he described as a “core modality in modern body contouring procedures.” He said the expansion would broaden AYON’s functionality by supporting multiple fat-removal modalities on a single platform and expand its addressable customer base. → Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30% Following clearance, Apyx plans to implement a limited commercial launch with targeted early adopters to refine training, optimize utilization, and evaluate the customer experience before scaling. Goodwin said the company will take a “disciplined approach” similar to its strategy ahead of AYON’s full launch. Goodwin told analysts that lack of power-assisted liposuction has been an adoption factor for some surgeons. “There are people that are waiting for power lipo before they get AYON because some doctors do not use ultrasonic liposuction,” he said, adding that the approval would “round out the liposuction capabilities of AYON.” Apyx highlighted strong international performance in the quarter. Chief Financial Officer Matt Hill said international revenue increased 63% year over year to $4.4 million, while domestic revenue rose 20% to $8.1 million. Goodwin cited early traction in South Korea following regulatory approval in December 2025. He said the company saw “solid interest around the Apyx One Console and single-use handpieces immediately following our regulatory approval,” adding that initial demand “exceeded expectations.” On plans to bring AYON outside the U.S., Goodwin said the company is working on registrations in various countries and intends to provide updates as progress is made. “We plan to have AYON registered everywhere in the world at some point in time,” he said. When asked about timing, Goodwin said he could not provide a specific timeline given country-by-country regulatory variability, but outlined priority regions including Europe, Latin America (specifically Brazil and Colombia), the Middle East, and key markets in Asia. Hill reported gross profit of $7.9 million, up from $5.7 million a year earlier. Gross margin increased to 63.5% from 60.1%, which Hill attributed primarily to segment mix, with Surgical Aesthetics making up a greater share of sales, as well as product mix within OEM. He said the margin improvement was “partially offset by geographic mix,” with international sales comprising a higher portion of revenue, and by tariffs that began affecting the company in the second half of 2025. Operating expenses were relatively flat at $8.8 million compared with $8.7 million in the prior-year period. Hill said the change reflected higher selling, general and administrative expenses and salaries, offset by lower research and development and professional services expenses. Loss from operations narrowed to $0.9 million from $3.1 million. Net loss attributable to stockholders was $2.1 million, or $0.05 per share, compared with $4.2 million, or $0.10 per share, a year earlier. Adjusted EBITDA loss improved to $0.3 million from an Adjusted EBITDA loss of $2.4 million. Cash used in operating activities was $0.6 million, compared with $0.7 million in the prior-year period. As of March 31, 2026, Apyx had $31.1 million in cash and cash equivalents. Hill said the company believes its projections, including AYON uptake, working capital management, and cost controls, “will yield cash through 2027.” Apyx raised its full-year 2026 revenue outlook. Hill said the company now expects total revenue of $59 million to $60 million, up from prior guidance of $57.5 million to $58.5 million. The updated forecast compares with $52.8 million reported for full-year 2025. Surgical Aesthetics revenue: $54 million to $55 million (previously $53 million to $54 million), compared with approximately $45.3 million in 2025. OEM revenue: approximately $5 million (previously $4.5 million), compared with approximately $7.5 million in 2025. Gross margin: approximately 62% to 63% depending on product and geographic mix. Operating expenses: not to exceed $45 million. Hill noted that while OEM revenue increased in the quarter to $1.8 million from $1.5 million due to higher volume with existing customers, the company expects OEM revenue to decrease for the year and over time as Apyx focuses on Surgical Aesthetics. Management also discussed demand trends tied to GLP-1 weight-loss drugs. Goodwin said the company believes rapid GLP-1 adoption is creating a growing need for solutions to treat loose and lax skin after weight loss, and that Renuvion and AYON are positioned to address that need in surgical body contouring. When asked about current procedure demand amid macro and geopolitical concerns, Goodwin said, “From a demand perspective, we’re still seeing patients coming into practices and wanting these procedures.” On tariffs, Goodwin said the company assumed tariffs would remain in place through the rest of the year and that they are reflected in guidance. He added that Apyx’s manufacturing footprint in Sofia, Bulgaria and Clearwater, Florida has helped the company “minimize the tariff impact so far.” Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company's product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology. Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions. The article "Apyx Medical Q1 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for May 2026.

Reported total revenue of $12.5 million in the first quarter of 2026 primarily driven by 36% growth in the Surgical Aesthetics segment Raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0 million Management to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its first quarter ended March 31, 2026. Recent Financial and Operating Highlights: Reported total revenue of $12.5 million in the first quarter of 2026, compared with $9.4 million in the same period last year. Surgical Aesthetics revenue increased to $10.7 million in the first quarter of 2026, compared with $7.9 million in the first quarter of 2025, which was the result of domestic sales of AYON, Renuvion generators internationally, and single use handpieces worldwide. OEM revenue was approximately $1.8 million in the first quarter of 2026, representing an increase of 13.8% from the same period last year. Net loss attributable to stockholders of $2.1 million in the first quarter of 2026, compared with a net loss attributable to stockholders of $4.2 million in the first quarter of 2025. Adjusted EBITDA loss was $0.3 million for the first quarter of 2026, compared with an Adjusted EBITDA loss of $2.4 million for the first quarter of 2025. International sales exceeded expectations, driven in part by sales of the Apyx One Console and single‑use handpieces in South Korea following regulatory approval in December 2025. South Korea represents an attractive growth market, with the cosmetic surgery market estimated at $1.7 billion in 2024 and projected to exceed $3.9 billion by 2031. Renuvion won the 2026 NewBeauty award for “Best Minimally Invasive Skin Tightener” for the second year in a row. “Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S., increasing demand for Renuvion internationally and an increase in handpieces worldwide,” said Charlie Goodwin, President and Chief Executive Officer. “During the quarter, our team delivered on several fronts, including growing Surgical Aesthetic sales including expansion of AYON and exceeding expectations in key international markets such as South Korea. Taken together, this performance reinforces our confidence in the business and supports our decision to raise our revenue outlook for the full year 2026.” The following tables present revenue by reportable segment and geography: First Quarter 2026 Results: Total revenue for the three months ended March 31, 2026 increased to $12.5 million, compared with $9.4 million in the prior year period. Surgical Aesthetics segment sales increased 36.1% or $2.8 million to approximately $10.7 million for the three months ended March 31, 2026, when compared with $7.9 million for the three months ended March 31, 2025. The Surgical Aesthetics sales increase was driven by sales of AYON, as the Company commenced the commercial launch in the third quarter of 2025, increased sales of generators internationally and increased volume of single-use handpieces in both domestic and international markets. These increases were partially offset by decreases in domestic sales of generators, including upgrades to the Apyx One Console, where the purchase of AYON was not part of the sale and upgrades to the Apyx One Console in international markets. OEM segment sales increased 13.8%, or approximately $0.2 million, to $1.8 million for the three months ended March 31, 2026, when compared with $1.5 million for the three months ended March 31, 2025. The increase in OEM sales was due to increases in sales volume to existing customers. While OEM segment sales increased for the three month period, with the increased focus on Surgical Aesthetics, it is expected that OEM segment revenue will decrease for the year and that this trend will continue over time. Gross profit for the three months ended March 31, 2026, increased to $7.9 million, compared with $5.7 million for the same period in the prior year. Gross margin for the three months ended March 31, 2026, was 63.5%, compared to 60.1% for the same period in 2025. The increase in gross margin for the three months ended March 31, 2026 from the prior year period is primarily attributable to mix between the Company’s segments with Surgical Aesthetics comprising a higher percentage of total sales and product mix within the OEM segment. This was partially offset by geographic mix, with international sales comprising a higher percentage of total sales and tariffs that began effecting the Company in the second half of 2025. Operating expenses were essentially flat at $8.8 million for the three-month periods ended March 31, 2026, compared with $8.7 million for the same period last year. The slight increase in operating expenses was driven by a $0.2 million increase in salaries and related costs and a $0.1 million increase in selling, general and administrative expenses. These increases were partially offset by a $0.1 million decrease in professional services and a $39,000 decrease in research and development. Other expense, net was relatively flat at $1.1 million for each of the three months ended March 31, 2026 and 2025. Net loss attributable to stockholders was $2.1 million, or $0.05 per share, for the three months ended March 31, 2026, compared with $4.2 million, or $0.10 per share, in the prior year period. Adjusted EBITDA loss for the three months ended March 31, 2026 was $0.3 million as compared with an Adjusted EBITDA loss of $2.4 million for the three months ended March 31, 2025. As of March 31, 2026, the Company had cash and cash equivalents of $31.1 million. Management believes based on its projections, including the uptake of the AYON platform, working capital management and its strict cost controls, the Company will yield cash through 2027. Financial Guidance for Full Year 2026: The Company announced an upward revision to select financial guidance targets for the year ending December 31, 2026: Total revenue in the range of $59.0 million to $60.0 million, up from the previous guidance of $57.5 million to $58.5 million. This is compared with $52.8 million reported for the year ended December 31, 2025. Total revenue guidance assumes: Surgical Aesthetics revenue is expected to be in the range of $54.0 million to $55.0 million, up from the previous guidance of $53.0 million to $54.0 million. This is compared with approximately $45.3 million reported for the year ended December 31, 2025. OEM revenue is expected to be approximately $5.0 million, up from $4.5 million. This is compared with approximately $7.5 million for the year ended December 31, 2025. The Company continues to expect operating expenses of less than $45.0 million for the year ended December 31, 2026. Conference Call Details: Management will host a conference call at 8:00 a.m. Eastern Time today, May 7th, to discuss the results of the first quarter ended March 31, 2026, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81537. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference. An archive of the webcast will be accessible approximately one hour after the live event ends on the Investor Relations section of the Company’s website (click here). Investor Relations Contact: Jeremy Feffer, Managing Director, LifeSci Advisors OP: 212-915-2568 [email protected] About AYON Body Contouring System™: AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery. About Apyx Medical Corporation: Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com. Cautionary Statement on Forward-Looking Statements: Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the “FDA”), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company’s financial performance. Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause the Company’s actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company’s ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. Use of Non-GAAP Financial Measure: The Company has presented the following non-GAAP financial measure in this press release: adjusted EBITDA. The Company defines adjusted EBITDA as its reported net loss attributable to stockholders (GAAP) plus income tax expense (benefit), interest income and expense, depreciation and amortization, stock-based compensation expense and other significant non-recurring items. We present the following non-GAAP measure of adjusted EBITDA because we believe such measure is a useful indicator of our operating performance. Our management uses adjusted EBITDA principally as a measure of our operating performance and believes that this measure is useful to investors because it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry. We also believe that this measure is useful to our management and investors as a measure of comparative operating performance from period to period. The non-GAAP financial measure presented in this release should not be considered as a substitute for, or preferable to, the measures of financial performance prepared in accordance with GAAP.